HK1048945A1 - Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies - Google Patents

Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Info

Publication number
HK1048945A1
HK1048945A1 HK03101198.5A HK03101198A HK1048945A1 HK 1048945 A1 HK1048945 A1 HK 1048945A1 HK 03101198 A HK03101198 A HK 03101198A HK 1048945 A1 HK1048945 A1 HK 1048945A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
patients
treatment
bone marrow
hodgkins lymphoma
Prior art date
Application number
HK03101198.5A
Inventor
William H Rastetter
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of HK1048945A1 publication Critical patent/HK1048945A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03101198.5A 1999-08-11 2003-02-18 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies HK1048945A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14828799P 1999-08-11 1999-08-11
PCT/US2000/040459 WO2001010462A1 (en) 1999-08-11 2000-07-25 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Publications (1)

Publication Number Publication Date
HK1048945A1 true HK1048945A1 (en) 2003-04-25

Family

ID=22525101

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101198.5A HK1048945A1 (en) 1999-08-11 2003-02-18 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Country Status (11)

Country Link
EP (1) EP1207906A4 (en)
JP (1) JP2003513012A (en)
CN (2) CN101259270A (en)
AU (1) AU784971B2 (en)
CA (1) CA2378646A1 (en)
HK (1) HK1048945A1 (en)
MX (1) MXPA02001398A (en)
MY (1) MY136635A (en)
NO (1) NO20020639L (en)
TW (1) TWI279233B (en)
WO (1) WO2001010462A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60024436T2 (en) 1999-05-07 2006-08-17 Genentech, Inc., South San Francisco TREATMENT OF AUTOIMMUNE DISEASES WITH ANTAGONISTS BINDING THE SURFACE MARKERS OF B CELLS
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
PL216630B1 (en) 2002-10-17 2014-04-30 Genmab As Human monoclonal antibodies against cd20
RS51318B (en) 2002-12-16 2010-12-31 Genentech Inc. Immunoglobulin variants and uses thereof
PL1613350T3 (en) 2003-04-09 2009-08-31 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
EP1626993B1 (en) 2003-05-09 2015-03-11 Duke University Cd20-specific antibodies and methods of employing same
KR20060027801A (en) 2003-06-05 2006-03-28 제넨테크, 인크. Combination therapy for b cell disorders
CA2544865C (en) 2003-11-05 2019-07-09 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
CN106075435A (en) 2004-06-04 2016-11-09 健泰科生物技术公司 For the method treating multiple sclerosis
EP1776384B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant fc regions
NI200800032A (en) 2005-07-25 2009-03-23 REDUCTION OF CELL B USING SPECIFIC JOINT MOLECULES CD37 AND CD20
WO2007014238A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
MX2008015524A (en) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function.
PL3327026T3 (en) 2007-07-09 2020-02-28 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
JP2011500715A (en) 2007-10-16 2011-01-06 ザイモジェネティクス， インコーポレイテッド Combination of BLyS inhibitor and anti-CD20 agent for the treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
SI2132228T1 (en) 2008-04-11 2011-10-28 Emergent Product Dev Seatle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CA2747326C (en) * 2008-12-22 2017-05-16 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JO3434B1 (en) 2009-07-31 2019-10-20 Millennium Pharm Inc Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
KR101822205B1 (en) 2009-08-11 2018-01-25 제넨테크, 인크. Production of proteins in glutamine-free cell culture media
CN102933231B (en) 2010-02-10 2015-07-29 伊缪诺金公司 CD20 antibody and uses thereof
BR112012020557A8 (en) 2010-02-19 2018-01-02 Millennium Pharm Inc crystalline forms of sodium 4 - {[9-chloro-7- (2-fluoro-6-methophenyl) -5h-pyrimido [5,4-d] [2] benzazepin-2-yl] amino} -2-methoxybenzoate
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
JP6360881B2 (en) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Combination of catalytic MTORC1 / 2 inhibitor and selective inhibitor of Aurora A kinase
CA2970738A1 (en) * 2015-01-23 2016-07-28 Immunomedics, Inc. Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
IL292708B1 (en) 2015-05-30 2024-04-01 Molecular Templates Inc De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
PE20221008A1 (en) 2015-06-24 2022-06-15 Hoffmann La Roche ENGINEERED AFFINITY ANTI-TRANSFERRIN RECEPTOR ANTIBODIES
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
PE20181004A1 (en) 2015-10-02 2018-06-26 Hoffmann La Roche BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
RU2019110955A (en) * 2016-09-16 2020-10-20 Нордик Нановектор Аса TREATMENT OF NECHODGKIN'S LYMPHOMA WITH LILOTOMAB AND 177Lu-LILOTOMAB WITH SATETHRAXETAN
CN108421048B (en) * 2016-09-28 2021-04-20 首都医科大学附属北京世纪坛医院 Nano active carbon targeted drug delivery system, preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL174721B1 (en) * 1992-11-13 1998-09-30 Idec Pharma Corp Monoclonal antibody anty-cd2
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DK1974747T3 (en) * 1998-08-11 2012-09-17 Biogen Idec Inc Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody

Also Published As

Publication number Publication date
JP2003513012A (en) 2003-04-08
CN101259270A (en) 2008-09-10
EP1207906A4 (en) 2005-07-06
AU7626000A (en) 2001-03-05
MXPA02001398A (en) 2002-08-12
WO2001010462A1 (en) 2001-02-15
CN1373671A (en) 2002-10-09
CN100389825C (en) 2008-05-28
EP1207906A1 (en) 2002-05-29
AU784971B2 (en) 2006-08-10
CA2378646A1 (en) 2001-02-15
TWI279233B (en) 2007-04-21
NO20020639L (en) 2002-04-11
MY136635A (en) 2008-11-28
NO20020639D0 (en) 2002-02-08

Similar Documents

Publication Publication Date Title
HK1048945A1 (en) Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
EP1227836A4 (en) Treatment of intermediate- and high-grade non-hodgkins lymphoma with anti-cd20 antibody
AUPQ893200A0 (en) Medical residue treatment
IL133571A0 (en) Medical instrument for treating biological tissue
GB2353220B (en) Surgical instrument
PT1066838E (en) Bone tissue regenerating composition
GB9926231D0 (en) Medical implants
PT1716853E (en) Treatment of cancers of the human body using et743
AU138426S (en) An electrode for medical use
PL358848A1 (en) Bone treatment material
HUP0001699A2 (en) Arrangement for decanting of blood
PL340948A1 (en) Syringe, in particular that for taking blood samples from patients
IL148051A0 (en) Finger-guided surgical instrument
AU5215300A (en) Dental treatment area
AU3177500A (en) Proteins for diagnosis and treatment of breast cancer
GB2353477B (en) Medical endoscope
IL143990A0 (en) Bone stimulating factor
EP1202751A4 (en) Medical sterilizer
GB9904252D0 (en) Composition for the treatment of pain
GB9819296D0 (en) Clinical table for treatment of the spine
AUPQ421299A0 (en) Treatment of bone disorder
GB2341314B (en) Medical patient suspension apparatus
GB9903558D0 (en) Medical treatment
AU140446S (en) Tissue processing instrument
GB9912076D0 (en) Appliance for medical treatment

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
CHPA Change of a particular in the register (except of change of ownership)